Is there a need to reconsider the use of metformin in COVID-19 patients with type 2 diabetes mellitus?

ABSTRACT:

Introduction

Diabetes has been linked with poorer outcomes in coronavirus disease (COVID-19) patients. However, the question to whether continue or withdraw metformin therapy in COVID-19 patients with type 2 diabetes mellitus remains contentious. This study aims to investigate the association between metformin and poor COVID-19 outcomes.

Methods

Eligible studies published up to 21 October 2020 were included and appraised for validity, importance, and applicability. The included studies were further ranked according to the level of evidence (LOE).

Results

Nine studies were included for further assessments, of which seven studies stated that metformin was not associated with poor COVID-19 outcomes (LOE II-V), while the other two with poorer designs stated otherwise (LOE

SUBMITTER: Lazarus G 

PROVIDER: S-EPMC7922709 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature